Swiftsure International Inc.
Holmes Biopharma, Inc.: Contracts and Revenue continue to grow

Holmes Biopharma Inc. / Miscellaneous



Corporate news transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Holmes Biopharma ? Contracts and Revenue continue to grow

Scottsdale, Arizona ? December 19, 2006, 2006 ? Holmes Biopharma, Inc.
(Berlin Common symbol ? HHJA, security code A0KDRX) (Berlin Reg S symbol ?
HHJB, security code A0KDR3) announces that sales efforts for it Phase 1
clinic in Omaha, Nebraska continue to show strong growth. The company had
revenue of approximately $200,000 in December 2006, and plans to reach the
$2 million mark on signed contracts by February 2007.

 'We have completed the first few projects and our clients are very pleased
with the level of service they received. We expect to see follow-up
projects from all these clients in first quarter of 2007' stated Sohail
Khattak, President and CEO of Qualia.

The Company expects solid first and second quarter bookings as clients are
planning their projects for next year.

On behalf of the Board of Directors 

John F. Metcalfe, President

Certain statements in this press release constitute 'forward looking
statements' within the meaning of the United States Securities Legislation.
The Company's actual results could differ from those in the forward-looking
statements. Do not construe this information as investment advice. This is
not a solicitation to buy or sell securities. This does not purport to be a
complete analysis of the Company. Investing in securities is speculative
and carries a high degree of risk. Past performance does not guarantee
future results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All information
contained in this press release should be independently investigated. This
press release contains forward-looking statements. These remarks involve
risks and uncertainties.  Risks are not limited to quarterly fluctuations
in results or the companies? management of growth and competition. Other
risks are detailed in the Company's SEC filings.  Actual results may differ
materially from such information set forth herein.

Contact:

John F. Metcalfe, President and CEO  
C/O Holmes Biopharma Inc.
www.holmesbiopharma.com
Tel: 001-877-241-4779 Email: ir@holmesbiopharma.com
8655 East Via De Ventura, G-200, Scottsdale AZ 85258






DGAP 20.12.2006 
----------------------------------------------------------------------